Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Continuing Education
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherBasic Science (Animal or Phantoms)
Open Access

Substitution of L-Trp by α-methyl-L-Trp in 177Lu-RM2 results in 177Lu-AMTG, a high affinity GRPR ligand with improved in vivo stability

Thomas Guenther, Sandra Deiser, Veronika Felber, Roswitha Beck and Hans-Juergen Wester
Journal of Nuclear Medicine January 2022, jnumed.121.263323; DOI: https://doi.org/10.2967/jnumed.121.263323
Thomas Guenther
Technical University of Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Thomas Guenther
Sandra Deiser
Technical University of Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Veronika Felber
Technical University of Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Veronika Felber
Roswitha Beck
Technical University of Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Juergen Wester
Technical University of Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hans-Juergen Wester
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

jnumed.121.263323
DOI 
https://doi.org/10.2967/jnumed.121.263323
PubMed 
35027371

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online January 13, 2022.

Article Versions

  • You are currently viewing a previous version of this article (January 13, 2022 - 13:12).
  • View the most recent version of this article
Copyright & Usage 
Copyright © 2022 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Thomas Guenther,
  2. Sandra Deiser,
  3. Veronika Felber,
  4. Roswitha Beck and
  5. Hans-Juergen Wester
  1. Technical University of Munich, Germany
  1. For correspondence or reprints contact: Thomas Guenther, Technical University of Munich, Walther-Meissner-Str. 3, Garching 85748, Germany. E-mail: thomas.guenther@tum.de

Statistics from Altmetric.com

Cited By...

  • 6 Citations
  • 10 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo
    Nadine Holzleitner, Thomas Günther, Roswitha Beck, Constantin Lapa, Hans-Jürgen Wester
    Pharmaceuticals 2022 15 12
  • Albumin-Mediated Size Exclusion Chromatography: The Apparent Molecular Weight of PSMA Radioligands as Novel Parameter to Estimate Their Blood Clearance Kinetics
    Jan-Philip Kunert, Sebastian Fischer, Alexander Wurzer, Hans-Jürgen Wester
    Pharmaceuticals 2022 15 9
  • Gastrin-releasing peptide receptor agonists and antagonists for molecular imaging of breast and prostate cancer: from pre-clinical studies to translational perspectives
    Joana Gorica, Maria Silvia De Feo, Luca Filippi, Viviana Frantellizzi, Orazio Schillaci, Giuseppe De Vincentis
    Expert Review of Molecular Diagnostics 2022 22 11
  • Bioorthogonal Chemistry Approach for the Theranostics of GRPR-Expressing Cancers
    Alice D’Onofrio, Francisco Silva, Lurdes Gano, Paula Raposinho, Célia Fernandes, Arkadiusz Sikora, Monika Wyczółkowska, Renata Mikołajczak, Piotr Garnuszek, António Paulo
    Pharmaceutics 2022 14 12
  • Development of the First 18F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety
    Thomas Günther, Nadine Holzleitner, Daniel Di Carlo, Nicole Urtz-Urban, Constantin Lapa, Hans-Jürgen Wester
    Pharmaceutics 2023 15 3
  • Optimization of the Pharmacokinetic Profile of [99mTc]Tc-N4-Bombesin Derivatives by Modification of the Pharmacophoric Gln-Trp Sequence
    Thomas Günther, Matthias Konrad, León Stopper, Jan-Philip Kunert, Sebastian Fischer, Roswitha Beck, Angela Casini, Hans-Jürgen Wester
    Pharmaceuticals 2022 15 9
  • Clinical Advances and Perspectives in Targeted Radionuclide Therapy
    Nicolas Lepareur, Barthélémy Ramée, Marie Mougin-Degraef, Mickaël Bourgeois
    Pharmaceutics 2023 15 6
  • Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs
    Nadine Holzleitner, Thomas Günther, Amira Daoud-Gadieh, Constantin Lapa, Hans-Jürgen Wester
    EJNMMI Research 2023 13 1
  • Preclinical Comparison of the64Cu- and68Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [68Ga]Ga-AMTG PET/CT
    Lena Koller, Markus Joksch, Sarah Schwarzenböck, Jens Kurth, Martin Heuschkel, Nadine Holzleitner, Roswitha Beck, Gunhild von Amsberg, Hans-Jürgen Wester, Bernd Joachim Krause, Thomas Günther
    Journal of Nuclear Medicine 2023
  • Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting
    T. S. T. Damiana, P. Paraïso, C. de Ridder, D. Stuurman, Y. Seimbille, S. U. Dalm
    European Journal of Nuclear Medicine and Molecular Imaging 2023

Article usage

Article usage: January 2022 to August 2023

AbstractFullPdf
Jan 20229890180
Feb 2022298098
Mar 2022224072
Apr 2022128046
May 2022140047
Jun 2022141041
Jul 2022137036
Aug 2022148035
Sep 2022491768139
Oct 202220026274
Nov 202211513167
Dec 20229341735
Jan 20235740931
Feb 20234437749
Mar 20237441645
Apr 20235029365
May 20235223656
Jun 20233524237
Jul 20233530866
Aug 20236537770
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (9)
Journal of Nuclear Medicine
Vol. 64, Issue 9
September 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Substitution of L-Trp by α-methyl-L-Trp in 177Lu-RM2 results in 177Lu-AMTG, a high affinity GRPR ligand with improved in vivo stability
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Substitution of L-Trp by α-methyl-L-Trp in 177Lu-RM2 results in 177Lu-AMTG, a high affinity GRPR ligand with improved in vivo stability
Thomas Guenther, Sandra Deiser, Veronika Felber, Roswitha Beck, Hans-Juergen Wester
Journal of Nuclear Medicine Jan 2022, jnumed.121.263323; DOI: 10.2967/jnumed.121.263323

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Substitution of L-Trp by α-methyl-L-Trp in 177Lu-RM2 results in 177Lu-AMTG, a high affinity GRPR ligand with improved in vivo stability
Thomas Guenther, Sandra Deiser, Veronika Felber, Roswitha Beck, Hans-Juergen Wester
Journal of Nuclear Medicine Jan 2022, jnumed.121.263323; DOI: 10.2967/jnumed.121.263323
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Keywords

  • Peptides
  • Radionuclide Therapy
  • radiopharmaceuticals
  • AMTG
  • GRPR
  • RM2
  • increased metabolic stability
  • prostate cancer
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire